A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 346,355 shares of VRTX stock, worth $141 Million. This represents 0.29% of its overall portfolio holdings.

Number of Shares
346,355
Previous 335,161 3.34%
Holding current value
$141 Million
Previous $157 Million 2.54%
% of portfolio
0.29%
Previous 0.3%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$460.0 - $505.78 $5.15 Million - $5.66 Million
11,194 Added 3.34%
346,355 $161 Million
Q2 2024

Aug 14, 2024

SELL
$392.81 - $485.53 $5.93 Million - $7.33 Million
-15,095 Reduced 4.31%
335,161 $157 Million
Q1 2024

May 15, 2024

BUY
$407.69 - $446.08 $20.4 Million - $22.3 Million
50,066 Added 16.68%
350,256 $146 Million
Q4 2023

Feb 14, 2024

BUY
$343.0 - $410.68 $63,798 - $76,386
186 Added 0.06%
300,190 $122 Million
Q3 2023

Nov 14, 2023

SELL
$338.18 - $362.46 $2.04 Million - $2.19 Million
-6,029 Reduced 1.97%
300,004 $104 Million
Q2 2023

Aug 14, 2023

SELL
$314.42 - $351.91 $10.2 Million - $11.4 Million
-32,357 Reduced 9.56%
306,033 $108 Million
Q1 2023

May 15, 2023

BUY
$283.23 - $323.1 $44.9 Million - $51.2 Million
158,500 Added 88.11%
338,390 $107 Million
Q4 2022

Feb 14, 2023

SELL
$285.76 - $321.48 $44.9 Million - $50.6 Million
-157,273 Reduced 46.65%
179,890 $51.9 Million
Q3 2022

Nov 14, 2022

SELL
$273.83 - $305.53 $64.3 Million - $71.8 Million
-234,867 Reduced 41.06%
337,163 $97.6 Million
Q2 2022

Aug 15, 2022

SELL
$234.96 - $292.55 $52 Million - $64.7 Million
-221,260 Reduced 27.89%
572,030 $161 Million
Q1 2022

May 16, 2022

BUY
$221.42 - $260.97 $127 Million - $149 Million
572,400 Added 259.13%
793,290 $207 Million
Q4 2021

Feb 14, 2022

BUY
$177.01 - $223.45 $8.31 Million - $10.5 Million
46,930 Added 26.98%
220,890 $48.5 Million
Q3 2021

Nov 15, 2021

SELL
$181.39 - $202.99 $29.9 Million - $33.5 Million
-164,980 Reduced 48.68%
173,960 $31.6 Million
Q2 2021

Aug 16, 2021

SELL
$187.49 - $221.1 $103 Million - $121 Million
-548,800 Reduced 61.82%
338,940 $68.3 Million
Q1 2021

May 17, 2021

BUY
$207.02 - $241.31 $42.6 Million - $49.6 Million
205,600 Added 30.14%
887,740 $191 Million
Q4 2020

Feb 16, 2021

BUY
$207.01 - $276.09 $81 Million - $108 Million
391,150 Added 134.42%
682,140 $161 Million
Q3 2020

Nov 16, 2020

SELL
$255.65 - $303.1 $27.8 Million - $32.9 Million
-108,662 Reduced 27.19%
290,990 $79.2 Million
Q2 2020

Aug 14, 2020

SELL
$225.48 - $295.8 $115 Million - $151 Million
-511,300 Reduced 56.13%
399,652 $116 Million
Q1 2020

May 15, 2020

BUY
$199.77 - $247.81 $20.2 Million - $25.1 Million
101,251 Added 12.5%
910,952 $217 Million
Q4 2019

Feb 14, 2020

SELL
$166.71 - $223.91 $10.5 Million - $14.1 Million
-62,800 Reduced 7.2%
809,701 $177 Million
Q3 2019

Nov 14, 2019

BUY
$166.23 - $187.09 $36.5 Million - $41 Million
219,360 Added 33.59%
872,501 $148 Million
Q2 2019

Aug 14, 2019

BUY
$164.61 - $190.37 $34.4 Million - $39.8 Million
208,900 Added 47.02%
653,141 $120 Million
Q1 2019

May 15, 2019

BUY
$163.73 - $194.7 $1.92 Million - $2.28 Million
11,729 Added 2.71%
444,241 $81.7 Million
Q4 2018

Feb 14, 2019

BUY
$151.91 - $192.21 $5.54 Million - $7.02 Million
36,500 Added 9.22%
432,512 $71.7 Million
Q3 2018

Nov 14, 2018

SELL
$167.73 - $192.74 $78 Million - $89.6 Million
-464,892 Reduced 54.0%
396,012 $76.3 Million
Q2 2018

Aug 14, 2018

BUY
$145.72 - $169.96 $29.2 Million - $34 Million
200,223 Added 30.31%
860,904 $146 Million
Q1 2018

May 15, 2018

SELL
$151.6 - $177.13 $106 Million - $124 Million
-698,600 Reduced 51.39%
660,681 $108 Million
Q4 2017

Feb 14, 2018

BUY
$137.28 - $155.55 $44.4 Million - $50.3 Million
323,100 Added 31.18%
1,359,281 $204 Million
Q3 2017

Nov 14, 2017

BUY
$148.13 - $162.24 $153 Million - $168 Million
1,036,181
1,036,181 $158 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Adage Capital Partners Gp, L.L.C. Portfolio

Follow Adage Capital Partners Gp, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.